1. Home
  2. AIHS vs CANF Comparison

AIHS vs CANF Comparison

Compare AIHS & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AIHS
  • CANF
  • Stock Information
  • Founded
  • AIHS 2014
  • CANF 1994
  • Country
  • AIHS China
  • CANF Israel
  • Employees
  • AIHS N/A
  • CANF N/A
  • Industry
  • AIHS Finance: Consumer Services
  • CANF Biotechnology: Pharmaceutical Preparations
  • Sector
  • AIHS Finance
  • CANF Health Care
  • Exchange
  • AIHS Nasdaq
  • CANF Nasdaq
  • Market Cap
  • AIHS 10.0M
  • CANF 9.4M
  • IPO Year
  • AIHS 2018
  • CANF N/A
  • Fundamental
  • Price
  • AIHS $0.87
  • CANF $1.55
  • Analyst Decision
  • AIHS
  • CANF Strong Buy
  • Analyst Count
  • AIHS 0
  • CANF 2
  • Target Price
  • AIHS N/A
  • CANF $14.00
  • AVG Volume (30 Days)
  • AIHS 25.4K
  • CANF 138.1K
  • Earning Date
  • AIHS 02-07-2025
  • CANF 02-03-2025
  • Dividend Yield
  • AIHS N/A
  • CANF N/A
  • EPS Growth
  • AIHS N/A
  • CANF N/A
  • EPS
  • AIHS N/A
  • CANF N/A
  • Revenue
  • AIHS $6,067,071.00
  • CANF $667,000.00
  • Revenue This Year
  • AIHS N/A
  • CANF $409.56
  • Revenue Next Year
  • AIHS N/A
  • CANF N/A
  • P/E Ratio
  • AIHS N/A
  • CANF N/A
  • Revenue Growth
  • AIHS 3.33
  • CANF N/A
  • 52 Week Low
  • AIHS $0.40
  • CANF $1.29
  • 52 Week High
  • AIHS $1.45
  • CANF $4.69
  • Technical
  • Relative Strength Index (RSI)
  • AIHS 42.04
  • CANF 43.14
  • Support Level
  • AIHS $0.86
  • CANF $1.55
  • Resistance Level
  • AIHS $0.93
  • CANF $1.64
  • Average True Range (ATR)
  • AIHS 0.09
  • CANF 0.10
  • MACD
  • AIHS -0.02
  • CANF 0.01
  • Stochastic Oscillator
  • AIHS 3.45
  • CANF 17.14

About AIHS Senmiao Technology Limited

Senmiao Technology Ltd is a holding company. The company's operating segment includes Automobile Transaction and Related Services focusing on the online ride-hailing industry in the People's Republic of China and Online ride-hailing platform Services through its own platform, Xixingtianxia. It generates maximum revenue from the Automobile Transaction and Related Services segment. Geographically, it derives revenue from China.

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Share on Social Networks: